- Azacitidine is a hypomethylating agent primarily used in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). It plays a crucial role in inhibiting abnormal DNA methylation, thereby restoring normal gene function and slowing disease progression
- The market growth is driven by the rising prevalence of hematological malignancies, increasing adoption of hypomethylating agents (HMAs) in first-line treatment, and the expanding geriatric population, which is more susceptible to these disorders
- In addition, innovations in drug delivery methods, such as the development of oral azacitidine (Onureg), are transforming treatment approaches by enhancing patient compliance and reducing hospital visits
- For instance, the approval of Onureg (oral azacitidine) has provided an alternative to injectable formulations, allowing for greater flexibility in treatment administration
